SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access

Patients with pathologically confirmed selected tumor types (at site or centrally);

Mandatory availability of adequate human biological material (HBM);

Centrally performed confirmation of HBM adequacy in terms of quality and quantity for SPECTA downstream project requirements;

Age ≥ 12 years;

Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule;

Written informed consent according to applicable legal and ethical requirements;